Hela Pharma AB v Hela Pharma Australasia Limited

Link copied
Case Copied 22 min read

IN THE COURT OF APPEAL OF NEW ZEALAND

CA165/03
CA206/03

BETWEENHELA PHARMA AB


Appellant

ANDHELA PHARMA AUSTRALASIA LIMITED


Respondent

Hearing:1 February 2005

Court:McGrath, Glazebrook and Hammond JJ

Counsel:J R F Fardell QC and T P Mullins for Appellant


P D McKenzie QC for Respondent

Judgment:17 February 2005 

JUDGMENT OF THE COURT

A        The appeals are dismissed.

BThe appellant is to pay costs of $7,500 to the respondent together with the reasonable disbursements of the respondent on the appeals.  In the event that the parties are unable to settle the disbursements, same are to be fixed by the Registrar.

REASONS

(Given by Hammond J)

Table of Contents

PARA NO
INTRODUCTION [1]
THE FACTS [3]
WAS THE ARBITRATION DISPLACED? [28]
THE INTERIM AWARD [33]
THE APPEAL AND APPLICATION TO THE HIGH COURT [39]
THE HIGH COURT DECISION [42]
THE SUBMISSIONS IN THIS COURT [52]
THE RELEVANT LEGAL PRINCIPLES [54]
THIS CASE [61]
CONCLUSION [71]

INTRODUCTION

[1]       We have before us appeals from a single judgment of Goddard J in CIV‑2002-485-201 and CIV-2002-485-1377 Wellington Registry delivered on 1 August 2003.  The same issues arose in both matters.  Essentially, the Judge declined to interfere with the decision of an arbitrator as to who the proper parties to the reference to arbitration before him are.

[2]       The central facts of the matters which have come before us are not now in dispute.  What is in dispute, is the proper characterisation of the relationship (if any) between the parties, at the relevant times.  In the result, we take essentially the same view of those issues as were taken by the arbitrator - and in more extended form - by Goddard J on the appeals to the High Court.  Those issues can only be appreciated in the particular factual context of this case, to which we now turn.

The facts

[3]       Hela i Falkoping AB (“HF”) was a Swedish company.  It was the product licence-holder of a herpes cream called “Herstat”, and certain other products.  We use the past tense with respect to “HF” for reasons we will come to later in this judgment.

[4]       HF wished to establish a distributor for these products in New Zealand, Australia, the South Pacific and Indonesia.  Hela Pharma Australasia Limited (“HAPL”), a New Zealand company, wished to become that distributor.

[5]       On 10 June 1996 HF entered into an agreement with HPAL and another in Norway (International Business Developments AS) to effect this enterprise.

[6]       The distribution agreement was signed by Mr Per Rabe (who was the president of HF) for that company, and by appropriate representatives of the other parties.

[7]       Broadly, HPAL was given the sole and exclusive right to distribute HF’s products in New Zealand, Australia, the South Pacific and Indonesia.  It was also given the first option to distribute the products in certain other Asian countries.

[8]       The agreement provided for HF to terminate the agreement on six months written notice; and for either party to the agreement to terminate it without notice if the other…

CaseChat AU logo

Keep reading for free

Create a free CaseChat account to read Hela Pharma AB v Hela Pharma Australasia Limited and more:

  • Read every judgment in full
  • Ask AI and get answers linked to paragraphs
  • See how each paragraph was cited in later cases
  • Download judgments as PDF or Word
Continue with Google

One click creates your free account or signs you in.

By continuing you agree to the Terms and Privacy Policy.

Details
Case
[2005] NZCA 11
Decision Date

CaseChat Overview and Summary

Hela Pharma AB, a Swedish company, and Hela Pharma Australasia Limited, a New Zealand company, were involved in a contractual dispute that was referred to arbitration. Hela Pharma AB sought to appeal the decisions of the arbitrator and the High Court, which had declined to interfere with the decision of the arbitrator as to who the proper parties to the reference to arbitration were. The central facts of the case were not in dispute, but what was in dispute was the proper characterisation of the relationship between the parties at the relevant times. The Court of Appeal dismissed the appeals, holding that the arbitrator and the High Court were correct to find that a new agreement had arisen between Hela Pharma Australasia Limited and Hela Pharma AB, and that the arbitration was still "alive". The Court held that there was ample evidence for the arbitrator and the Judge to find that the consent of the necessary parties could be inferred from the conduct of the parties, and that there was consideration for a novation of this kind. The Court also held that the consent of all parties was required, and that the consent of Hela Pharma Australasia Limited was required to the new agreement. The Court found that there was quite sufficient knowledge for consent to be inferred, as the arbitrator and Judge did. The appeals were dismissed, and Hela Pharma AB was ordered to pay costs of $7,500 to Hela Pharma Australasia Limited together with the reasonable disbursements of Hela Pharma Australasia Limited on the appeals.

Orders

Orders of the court

Full text does not contain this section.

Background

Background to the litigation

Full text does not contain this section.

Evidence

Evidence Before The Court

Full text does not contain this section.

Decision

Reasons for decision

Full text does not contain this section.

Ratio Decidendi

Legal Principle Established

Full text does not contain this section.